Lv3
210 积分 2021-07-26 加入
Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies
2个月前
已完结
Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor
3个月前
已完结
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
3个月前
已完结
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
3个月前
已完结
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
4个月前
已完结
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
5个月前
已完结
A renaissance for YES in cancer
8个月前
已完结
YES1: A Novel Therapeutic Target and Biomarker in Cancer
8个月前
已完结
Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis
9个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
9个月前
已完结
皖公网安备34019202002308
